Michael S. Wyzga, Director at Akebia Therapeutics, Inc. (AKBA), bought 1,500 shares at $17.00 ($26K) on 2014-03-25, disclosed to the SEC on 2014-03-27.
Open-market purchase of $26k AKBA by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| Filing → |
| EXAS | SELL | 2019-08-02 | $590K | — | Filing → |
| EXAS | SELL | 2019-03-01 | $48K | — | Filing → |
| EXAS | SELL | 2018-08-30 | $369K | — | Filing → |